The independent financial analyst theScreener just requalified the general evaluation of INVITAE (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date January 14, 2022, the closing price was USD 11.74 ...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Two Directors at Invitae Corp gave away/sold 320,597 shares at between 0.000USD and 48.618USD. The significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
SAN FRANCISCO--(BUSINESS WIRE)-- Invitae Corporation (NYSE:NVTA), one of the fastest growing genetic information companies, has seen a significant increase in genetic testing for prostate cancer since the publication of landmark data showing testing may be underutilized when screening for and treating the second most common cancer in men. The company’s panel is the most comprehensive and affordable genetic test available to urologists and oncologists who treat men with prostate cancer, establishing the company as a new leader i...
SAN FRANCISCO--(BUSINESS WIRE)-- Invitae Corporation (NYSE:NVTA), a genetic information company, and TME Research, LLC today announced the initiation of a new clinical collaboration to evaluate the benefits of universal genetic testing of breast cancer patients. TME Research represents more than 300 breast care practices around the country whose core mission is to improve the quality and access to targeted breast cancer care. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/ne...
SAN FRANCISCO--(BUSINESS WIRE)-- Invitae Corporation (NYSE:NVTA), a genetic information company, today announced the expansion of its Breast Cancer STAT Panel with the addition of two important breast cancer predisposition genes – ATM and CHEK2 – and a faster turnaround time (TAT) with results available in as few as five days at no additional cost. The announcement was made at the San Antonio Breast Cancer Symposium (SABCS). “Recent research underscores the clinical utility of ATM and CHEK2 in making treatment d...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.